Results 21 to 30 of about 532,092 (302)

Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update [PDF]

, 2017
Summary: Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents.
A Alvarado-Miranda, A Kollár, C Léauté-Labrèze, CR Antonescu, D Belotti, E Itakura, E Pasquier, H Wong, I Ray-Coquard, IL Ray-Coquard, JM Stiles, L Jonker, LS Rosen, M Agulnik, N Penel, N Penel, O Mir, O Mir, Penella J. Woll, RG Maki, RJ Young, RJ Young, RJ Young, Robin J. Young, S Attia, S Behjati, S Sleijfer, S Zhou, V Raina, W Penella, WD Tap, WT Graaf van der   +31 more
core   +1 more source

Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization

Delhi Journal of Ophthalmology, 2011
Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue
Srivatsa Sehra, Reetika
doaj   +1 more source

Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report

International Breastfeeding Journal, 2022
Background Ranibizumab is one of intravitreal anti-vascular endothelial growth factor agents. It is applied in the treatments of choroidal neovascularization, age-related macular degeneration, diabetic macular edema, and macular edema secondary to ...
Ying Huang, Rong Zhou, Zuhua Sun, Yihan Zheng, Bing Lin   +4 more
doaj   +1 more source

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [PDF]

, 2013
Colorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy.
Cooper, Chris, Crathorne, Louise, Hoyle, M, Hyde, C, Jones-Hughes, T, Napier, Mark, Peters, J, Tappenden, P   +7 more
core   +2 more sources

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Acta Pharmaceutica, 2022
Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular ...
VAVLUKIS ANA, VAVLUKIS MARIJA, DIMOVSKI ALEKSANDAR, PETRUSHEVSKA GORDANA, EFTIMOV ALEKSANDAR, DOMAZETOVSKA SASHKA, MLADENOVSKA KRISTINA   +6 more
doaj   +1 more source

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab [PDF]

, 2011
The aim of this study is to evaluate the influence of germline vascular endothelial growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody bevacizumab (Bev) in metastatic colorectal cancer (MCRC ...
De Marchis, ML, Del Monte, G, Formica, V, Grenga, I, Guadagni, F, Ludovici, G, Palmirotta, R, Roselli, M, Savonarola, A, Schirru, M   +9 more
core   +1 more source

Newly Identified Peptide, Peptide Lv, Promotes Pathological Angiogenesis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background We recently discovered a small endogenous peptide, peptide Lv, with the ability to activate vascular endothelial growth factor receptor 2 and its downstream signaling.
Liheng Shi, Min Zhao, Colette A. Abbey, Shu‐Huai Tsai, Wankun Xie, Dylan Pham, Samantha Chapman, Kayla J. Bayless, Travis W. Hein, Robert H. Rosa, Michael L. Ko, Lih Kuo, Gladys Y.‐P. Ko   +12 more
doaj   +1 more source

TFEB‐translocated and ‐amplified renal cell carcinoma with VEGFA co‐amplification: A case of long‐term control by multimodal therapy including a vascular endothelial growth factor‐receptor inhibitor

IJU Case Reports, 2023
Introduction Renal cell carcinoma with TFEB amplification is rare and reportedly aggressive. We herein report a case of renal cell carcinoma with TFEB translocation and amplification in which long‐term control was achieved by multimodal therapy including
Hajime Takamori, Akiko Miyagi Maeshima, Ikuma Kato, Masaya Baba, Eijiro Nakamura, Yoshiyuki Matsui   +5 more
doaj   +1 more source

Immunohistochemical Expression of Vascular Endothelial Growth Factor and Its Correlation with Tumor Grade in Breast Ductal Carcinoma [PDF]

Acta Medica Iranica, 2011
Breast cancer is the most common cause of cancer-related death in female, after lung cancer. Angiogenesis is essential for tumor growth and metastasis; therefore, antiangiogenesis strategies for treatment of cancer are currently an issue of interest. The
Maryam Ghasemi, Omid Emadian, Farshad Naghshvar, Ahmadreza Bekhradnia, Saeid Abediankenari, Laleh Vahedi Larijani, Roghaieh Moghimpour   +6 more
doaj   +1 more source

Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment. [PDF]

PLoS ONE, 2013
There is much evidence that hypoxia in the tumor microenvironment enhances tumor progression. In an earlier study, we reported abnormal phenotypes of tumor-associated endothelial cells such as those resistant to chemotherapy and chromosomal instability ...
Miyako Kondoh, Noritaka Ohga, Kosuke Akiyama, Yasuhiro Hida, Nako Maishi, Alam Mohammad Towfik, Nobuo Inoue, Masanobu Shindoh, Kyoko Hida   +8 more
doaj   +1 more source